Immune reactions to clinical carcinogens and steroid hormones in breast pre-cancer and cancer patients

Cover Page

Cite item

Abstract

Detection of postmenopausal women at high risk for breast pre-cancer and cancer is a key condition to prevent these diseases. Aim of our research was to study possible usage of immunoassay for antibodies specific to benzo[a]pyrene, estradiol, and progesterone (IgA-Bp, IgA-Es, IgA-Pg) in determination of personal risks for fibrocystic disease and breast cancer at the early stage, with respect to hormone receptor status in tumor tissues. Blood serum IgA-Bp, IgA-Es, IgA-Pg were studied by ELISA in postmenopausal women: healthy controls (n = 401), patients with fibrocystic breast disease (n = 50), and breast cancer (stage I, n = 575, stages II-IV, n = 861). High individual IgA-Bp/IgA-Pg ratios of > 1.5 were found in 19.7% of healthy women, and in 50.0% of fibrocystic breast disease patients (p < 0.0001; OR = 4.1). IgA-Es/IgA-Pg ratios of > 1.0 were revealed in 48.4% healthy women and in 68.0% fibrocystic breast disease patients (p < 0.01; OR = 2.3). IgA-Bp/IgAPg values > 1.0 were found in 41.9% of healthy women, and, at higher rates, in the patients with breast cancer stage I: 68.3% ER- tumors (p < 0.0001; OR = 3.0) and 75.9% ER+ tumors (p < 0.0001; OR = 4.4). IgA-Es/ IgA-Pg ratios > 1.0 were revealed in 48.4% of healthy women, and in patients with breast cancer stage I: 65.3% ER- tumors (p < 0.003; OR = 2.0), and 76.8% ER+ tumors (p < 0.0001; OR = 3.5). Some associations of studied antibodies with cancer progression were revealed. Frequency of individual cases with IgA-Bp/IgA-Pg > 1.0 in patients with ER- tumors increased from 12.0% at stage I to 19.9% at stage II. Frequency of cases with IgA-Bp/IgA-Pg > 1.0 in the patients with ER+ tumors decreased from 62.0% at stage I to 57.3% at stage II (p = 0.002). Frequency of cases with IgA-Es/IgA-Pg > 1.0 in the patients with ER- tumors increased from 11.5% at stage I to 21.4% at stage II. Frequency of cases with IgA-Es/IgA-Pg > 1.0 in patients with ER+ tumors decreased from 63.3% at stage I to 56.1% at stage II (p < 0.001). The cases with individual excessive IgA-Bp and IgA-Es levels are associated with fibrocystic breast disease and ER+ breast cancer at the onset of the disease. Breast cancer progression was associated with the relative decrease of ER in tumor tissues, along with higher individual levels of IgA-Bp and IgА-Es and lower IgA-Pg levels. ELISA testing of IgА-Bp, IgА-Es, IgA-Pg could be recommended for detection of individual risk for fibrocystic breast disease and stage I of breast cancer, as well as for more efficient prevention and therapy by selective modulators of estrogen receptor (raloxifene, arzoxifene and lasofoxifine) and aromatase inhibitors (exemestane, anastrozole).

About the authors

A. N. Glushkov

Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry

Email: glushkovan@ihe.sbras.ru
ORCID iD: 0000-0002-8560-6719

Glushkov Andrew N., PhD, MD (Medicine), Professor, Chief Research Associate, Laboratory of Immunogenetics, Institute of Human Ecology

Kemerovo

SPIN-код (РИНЦ) 9536-8530;

AuthorID (Scopus) 7006323832;

ResearcherID (WOS) Q-5985-2016

Russian Federation

E. G. Polenok

Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry;
Kemerovo State Medical University

Email: egpolenok@mail.ru
ORCID iD: 0000-0002-9368-2340

Polenok Elena G., PhD (Pharmacy), Leading Research Associate, Laboratory of Immunochemistry, Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry; Associate Professor, Department of Biology with the Basics of Genetics and Parasitology, Kemerovo State Medical University

Kemerovo

SPIN-код (РИНЦ) 3925-0185;

AuthorID (Scopus) 6506567994;

ResearcherID (WOS) Q-5381-2016

Russian Federation

L. A. Gordeeva

Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry

Email: gorsib@rambler.ru
ORCID iD: 0000-0001-5870-7584

Gordeeva Ludmila A., PhD (Biology), Leading Research Associate, Laboratory of Immunogenetics, Institute of Human Ecology

Kemerovo

SPIN-код (РИНЦ) 6662-4616;

AuthorID (Scopus) 14052058500;

ResearcherID (WOS) R-2781-2016

Russian Federation

S. A. Mun

Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry

Author for correspondence.
Email: stellamun@yandex.ru
ORCID iD: 0000-0002-5530-3469

Mun Stella A., PhD (Medicine), Senior Research Associate, Laboratory of Immunogenetics, Institute of Human Ecology

650065, Kemerovo, Leningradsky ave, 10

SPIN-код (РИНЦ) 5579-8939;

AuthorID (Scopus) 7101645456;

ResearcherID (WOS) J-6484-2018

Russian Federation

M. V. Kostyanko

Kemerovo State University

Email: kmvksu@mail.ru

Kostyanko Mikhail V., Leading Engineer, Department of Organic Chemistry

Kemerovo

SPIN-код (РИНЦ) 5953-6554;

Author ID (Scopus) 6507008191

 

Russian Federation

G. I. Kolpinckiy

Kemerovo State Medical University;
Kemerovo Clinical Diagnostic Сenter

Email: Glebss@mail.ru

Kolpinsky Gleb I., PhD, MD (Medicine), Professor, Department of Radiology, Radiotherapy and Oncology, Kemerovo State Medical University; Main Physician, Kemerovo Clinical Diagnostic Сenter

Kemerovo

SPIN-код (РИНЦ) 6894-6419,

AuthorID (Scopus) 56677706300

Russian Federation

I. A. Vafin

Kuzbass Center of Blood

Email: gkuz.kots@yandex.ru

Chief Physician

Kemerovo

Russian Federation

A. V. Antonov

Kuzbass Clinical Oncology Dispensary

Email: al0412@mail.ru

Antonov Alexander  V., Head, Oncological Department No. 5

Kemerovo

Russian Federation

N. E. Verzhbitskaja

Kuzbass Clinical Oncology Dispensary

Email: verzhbitskaja@mail.ru

Verzhbitskaya Natalia E., PhD (Medicine), Chief, Department of Pathology

Kemerovo

Russian Federation

References

  1. Глушков А.Н., Поленок Е.Г., Мун С.А., Гордеева Л.А., Костянко М.В., Колпинский Г.И., Луценко В.А., Антонов А.В., Титов В.А., Вафин И.А. Антитела к химическим канцерогенам и половым стероидам и содержание эстрадиола и прогестерона в сыворотке крови женщин больных раком молочной железы и мужчин больных раком легкого // Российский иммунологический журнал, 2020. Т. 23, № 1. С. 69-78.
  2. Глушков А.Н., Поленок Е.Г., Мун С.А., Гордеева Л.А., Костянко М.В., Антонов А.В., Вержбицкая Н.Е., Вафин И.А. Индивидуальный иммунологический фенотип и риск рака молочной железы у женщин в постменопаузе // Российский иммунологический журнал, 2019. Т. 13, № 1. С. 44-52.
  3. Состояние онкологической помощи населению России в 2019 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.
  4. Шашова Е.Е., Кондакова И.В., Сломинская Е.М., Глущенко С.А. Сравнительное изучение содержания рецепторов эстрогенов и прогестерона в неизменной, опухолевой и метастатической тканях при раке молочной железы // Сибирский онкологический журнал, 2008. Т. 4, № 28. С. 42-45.
  5. Chaudhri R.A., Olivares-Navarrete R., Cuenca N., Hadadi A., Boyan B.D., Schwartz Z. Membrane estrogen signaling enhances tumorogenesis and metastatic potential of breast cancer cells via estrogen receptor-α 36 (ERα36). J. Biol. Chem., 2012, Vol. 287, no. 10, pp. 7169-7181.
  6. Dimou N.L., Papadimitriou N., Gill D., Christakoudi S., Murphy N., Gunter M. J., Travis R.C., Key T.J., Fortner R.T., Haycock P.C., Lewis S.J., Muir K., Martin R.M., Tsilidis K.K. Sex hormone binding globulin and risk of breast cancer: a Mendelian randomization study. Int. J. Epidemiol., 2019, Vol. 48, no. 3, pp. 807-816.
  7. Fortunati N., Catalano M.G., Boccuzzi G., Frairia R. Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer. Mol. Cell. Endocrinol., 2010, Vol. 316, no. 1, pp. 86-92.
  8. Hajian-Tilaki K. Receiver Operating Characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J. Intern. Med., 2013, Vol. 4, no. 2, pp. 627-635.
  9. LaCroix A.Z., Powles T., Osborne C.K., Wolter K., Thompson J.R., Thompson D.D., Allred D.C., Armstrong R., Cummings S.R., Eastell R., Ensrud K.E., Goss P., Lee A., Neven P., Reid D.M., Curto M., Vukicevic S. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J. Natl. Cancer Inst., 2010, Vol. 102, no. 22, pp. 1706-1715.
  10. Maselli A., Capoccia S., Pugliese P., Raggi C., Cirulli F., Fabi A., Malorni W., Pierdominici M., Ortona E. Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their level correlate with breast cancer cell proliferation. Oncoimmunology, 2016, Vol. 5, no. 2, e1074375. doi: 10.1080/2162402X.2015.1074375.
  11. Ortona E., Pierdominici M., Berstein L. Autoantibodies to estrogen receptors and their involvement in autoimmune diseases and cancer. J. Steroid Biochem. Mol. Biol., 2014, Vol. 144, Pt B, pp. 260-267.
  12. Sestak I. Preventative therapies for healthy women at high risk of breast cancer. Cancer Manag. Res., 2014, no. 6, pp. 423-430.
  13. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J. Clin., 2019, Vol. 69, no. 1, pp. 7-34.
  14. Vogel V.G. Role of hormones in cancer prevention. Am. Soc. Clin. Oncol. Educ. Book, 2014, pp. 34-40.

Supplementary files

There are no supplementary files to display.


Copyright (c) 2021 Glushkov A.N., Polenok E.G., Gordeeva L.A., Mun S.A., Kostyanko M.V., Kolpinckiy G.I., Vafin I.A., Antonov A.V., Verzhbitskaja N.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Свидетельство о регистрации СМИ ПИ № 77 - 11525 от 04.01.2002 выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies